These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28132529)

  • 1. Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes.
    Strong J; Kruger D; Novak L
    Curr Med Res Opin; 2017 Apr; 33(4):785-793. PubMed ID: 28132529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.
    Owens DR
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):977-87. PubMed ID: 27453980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus.
    Brown MA; Davis CS; Fleming LW; Fleming JW
    J Am Assoc Nurse Pract; 2016 Sep; 28(9):503-9. PubMed ID: 26990724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [INSULIN GLARGINE 300 U/mL (TOUJEO®)].
    Scheen AJ
    Rev Med Liege; 2016 Feb; 71(2):101-7. PubMed ID: 27141654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
    Becker RH; Dahmen R; Bergmann K; Lehmann A; Jax T; Heise T
    Diabetes Care; 2015 Apr; 38(4):637-43. PubMed ID: 25150159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction.
    Berard L; Cameron B; Woo V; Stewart J
    Can J Diabetes; 2015 Aug; 39(4):296-301. PubMed ID: 25819531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
    Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
    Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
    Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
    Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus.
    Clements JN; Bello L
    Am J Health Syst Pharm; 2016 Mar; 73(6):359-66. PubMed ID: 26953280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
    Bonadonna RC; Renard E; Cheng A; Fritsche A; Cali A; Melas-Melt L; Umpierrez GE
    Diabetes Res Clin Pract; 2018 Aug; 142():19-25. PubMed ID: 29649539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
    Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
    J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
    Xu P; Ye X; Zhang Y; Yuan Q; Liu M; Wu Q; Ren G; Li D
    J Diabetes Complications; 2015; 29(1):5-12. PubMed ID: 25456819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
    Lajara R; Cengiz E; Tanenberg RJ
    Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.
    Clements JN; Threatt T; Ward E; Shealy KM
    Clin Pharmacokinet; 2017 May; 56(5):449-458. PubMed ID: 27699623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
    Blair HA; Keating GM
    Drugs; 2016 Mar; 76(3):363-74. PubMed ID: 26821280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.